Abstract
Background: Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarilytargeting somatostatin receptor (sstr) subtypes 2 and 5, in neuroendocrine tumors (NET). Pasireotide, a second-generationSSA, targets multiple sstr subtypes. We compared the efficacy and safety of pasireotide plus everolimus to everolimus alone inpatients with advanced, well-differentiated, progressive pancreatic NET. Patients and methods: Patients were randomized 1: 1 to receive a combination of everolimus (10 mg/day, orally) andpasireotide long-acting release (60 mg/28 days, intramuscularly) or everolimus alone (10 mg/day, orally); stratified by prior SSAuse, and baseline serum chromogranin A and neuron-specific enolase. The primary end point was progression-free survival(PFS). Secondary end points included overall survival, objective response rate, disease control rate, and safety. Biomarker responsewas evaluated in an exploratory analysis. Results: Of 160 patients enrolled, 79 were randomized to the combination arm and 81 to the everolimus arm. Baseline demographicsand disease characteristics were similar between the treatment arms. No significant difference was observed in PFS: 16.8months incombination arm versus 16.6months in everolimus arm (hazard ratio, 0.99; 95% confidence interval, 0.64-1.54). Partial responses wereobserved in 20.3% versus 6.2% of patients in combination arm versus everolimus arm; however, overall disease control rate was similar(77.2% versus 82.7%, respectively). No significant improvement was observed inmedian overall survival. Adverse events were consistentwith the known safety profile of both the drugs; grade 3 or 4 fasting hyperglycemia was seen in 37% versus 11% of patients, respectively. Conclusions: The addition of pasireotide to everolimus was not associated with the improvement in PFS compared witheverolimus alone in this study. Further studies to delineate mechanisms by which SSAs slow tumor growth in NET are warranted.
| Original language | English |
|---|---|
| Article number | mdx078 |
| Pages (from-to) | 1309-1315 |
| Number of pages | 7 |
| Journal | Annals of Oncology |
| Volume | 28 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2017 |
Fingerprint
Keywords
- Everolimus
- Insulinlike growth factor-1
- mTOR signaling
- Pancreatic neuroendocrine tumors
- Pasireotide LAR
- Somatostatin analog
ASJC Scopus subject areas
- Hematology
- Oncology
Cite this
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors : COOPERATE-2 trial. / Kulke, M. H.; Ruszniewski, P.; Van Cutsem, E.; Lombard-Bohas, C.; Valle, J. W.; De Herder, W. W.; Pavel, M.; Degtyarev, E.; Brase, J. C.; Bubuteishvili-Pacaud, L.; Voi, M.; Salazar, R.; Borbath, I.; Fazio, N.; Smith, D.; Capdevila, J.; Riechelmann, R. P.; Yao, J. C.
In: Annals of Oncology, Vol. 28, No. 6, mdx078, 01.06.2017, p. 1309-1315.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors
T2 - COOPERATE-2 trial
AU - Kulke, M. H.
AU - Ruszniewski, P.
AU - Van Cutsem, E.
AU - Lombard-Bohas, C.
AU - Valle, J. W.
AU - De Herder, W. W.
AU - Pavel, M.
AU - Degtyarev, E.
AU - Brase, J. C.
AU - Bubuteishvili-Pacaud, L.
AU - Voi, M.
AU - Salazar, R.
AU - Borbath, I.
AU - Fazio, N.
AU - Smith, D.
AU - Capdevila, J.
AU - Riechelmann, R. P.
AU - Yao, J. C.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background: Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarilytargeting somatostatin receptor (sstr) subtypes 2 and 5, in neuroendocrine tumors (NET). Pasireotide, a second-generationSSA, targets multiple sstr subtypes. We compared the efficacy and safety of pasireotide plus everolimus to everolimus alone inpatients with advanced, well-differentiated, progressive pancreatic NET. Patients and methods: Patients were randomized 1: 1 to receive a combination of everolimus (10 mg/day, orally) andpasireotide long-acting release (60 mg/28 days, intramuscularly) or everolimus alone (10 mg/day, orally); stratified by prior SSAuse, and baseline serum chromogranin A and neuron-specific enolase. The primary end point was progression-free survival(PFS). Secondary end points included overall survival, objective response rate, disease control rate, and safety. Biomarker responsewas evaluated in an exploratory analysis. Results: Of 160 patients enrolled, 79 were randomized to the combination arm and 81 to the everolimus arm. Baseline demographicsand disease characteristics were similar between the treatment arms. No significant difference was observed in PFS: 16.8months incombination arm versus 16.6months in everolimus arm (hazard ratio, 0.99; 95% confidence interval, 0.64-1.54). Partial responses wereobserved in 20.3% versus 6.2% of patients in combination arm versus everolimus arm; however, overall disease control rate was similar(77.2% versus 82.7%, respectively). No significant improvement was observed inmedian overall survival. Adverse events were consistentwith the known safety profile of both the drugs; grade 3 or 4 fasting hyperglycemia was seen in 37% versus 11% of patients, respectively. Conclusions: The addition of pasireotide to everolimus was not associated with the improvement in PFS compared witheverolimus alone in this study. Further studies to delineate mechanisms by which SSAs slow tumor growth in NET are warranted.
AB - Background: Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarilytargeting somatostatin receptor (sstr) subtypes 2 and 5, in neuroendocrine tumors (NET). Pasireotide, a second-generationSSA, targets multiple sstr subtypes. We compared the efficacy and safety of pasireotide plus everolimus to everolimus alone inpatients with advanced, well-differentiated, progressive pancreatic NET. Patients and methods: Patients were randomized 1: 1 to receive a combination of everolimus (10 mg/day, orally) andpasireotide long-acting release (60 mg/28 days, intramuscularly) or everolimus alone (10 mg/day, orally); stratified by prior SSAuse, and baseline serum chromogranin A and neuron-specific enolase. The primary end point was progression-free survival(PFS). Secondary end points included overall survival, objective response rate, disease control rate, and safety. Biomarker responsewas evaluated in an exploratory analysis. Results: Of 160 patients enrolled, 79 were randomized to the combination arm and 81 to the everolimus arm. Baseline demographicsand disease characteristics were similar between the treatment arms. No significant difference was observed in PFS: 16.8months incombination arm versus 16.6months in everolimus arm (hazard ratio, 0.99; 95% confidence interval, 0.64-1.54). Partial responses wereobserved in 20.3% versus 6.2% of patients in combination arm versus everolimus arm; however, overall disease control rate was similar(77.2% versus 82.7%, respectively). No significant improvement was observed inmedian overall survival. Adverse events were consistentwith the known safety profile of both the drugs; grade 3 or 4 fasting hyperglycemia was seen in 37% versus 11% of patients, respectively. Conclusions: The addition of pasireotide to everolimus was not associated with the improvement in PFS compared witheverolimus alone in this study. Further studies to delineate mechanisms by which SSAs slow tumor growth in NET are warranted.
KW - Everolimus
KW - Insulinlike growth factor-1
KW - mTOR signaling
KW - Pancreatic neuroendocrine tumors
KW - Pasireotide LAR
KW - Somatostatin analog
UR - http://www.scopus.com/inward/record.url?scp=85021179457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021179457&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdx078
DO - 10.1093/annonc/mdx078
M3 - Article
C2 - 28327907
AN - SCOPUS:85021179457
VL - 28
SP - 1309
EP - 1315
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 6
M1 - mdx078
ER -